jiayi-li23/proxann_data huggingface dataset:
Bill 114-S-318 — Health / R&D
Subject: Health

Accelerating Biomedical Research Act 

This bill amends the Balanced Budget and Emergency Deficit Control Act of 1985 to require certain adjustments to discretionary spending limits in FY2016-FY2021 to accommodate increases in appropriations to the National Institutes of Health at the Department of Health and Human Services.
Bill 114-S-320 — Health / R&D
Subject: Health

Medical Innovation Act of 2015

This bill amends the Public Health Service Act to require certain drug manufacturers to make payments to fund research supported by the Food and Drug Administration (FDA) and the National Institutes of Health (NIH).

A drug manufacturer with over $1 billion in net income in a fiscal year that has entered into a settlement agreement in the previous five years with a federal agency regarding specified violations must pay 1% of its net income to the Department of Health and Human Services (HHS) for each of its covered blockbuster drugs. A covered blockbuster drug is a drug that has at least $1 billion in net sales in a year and was developed, in whole or in part, through federal investments in medical research, including a drug for which a patent contains information that relates to, or is based upon, federally-funded research.

Each fiscal year, HHS must publish a list of manufacturers that make payments, each manufacturer's covered blockbuster drugs, and payment amounts.

Payments are divided between the FDA and the NIH in proportion to the discretionary funding of those agencies, excluding FDA user fees. Payments are not disbursed if appropriations for the FDA or the NIH are lower than in the prior fiscal year.

The FDA's priority use for payments must include advancing regulatory science for medical products.

The NIH's priority use for payments must include supporting: (1) research that fosters radical innovation, (2) research that advances fundamental knowledge, (3) research related to diseases that disproportionately account for federal health care spending, and (4) early career scientists.

A covered blockbuster drug for which a manufacturer has not made a required payment is considered misbranded and cannot be sold until payment is made.
Bill 114-S-746 — Health / R&D
Subject: Health

Accelerating the End of Breast Cancer Act of 2015

Establishes the Commission to Accelerate the End of Breast Cancer to help end breast cancer by January 1, 2020.

Directs the Commission to identify, recommend, and promote initiatives, partnerships, and research that can be turned into strategies to prevent breast cancer and breast cancer metastasis while giving priority to those that are: (1) not prioritized in the public sector, and (2) unlikely to be achieved by the private sector due to technical and financial uncertainty.

Requires the Commission to: (1) submit within six months to the President and to the relevant congressional committees a description of the Commission's strategic plan; (2) submit an annual report to the President, Congress, and the public; and (3) ensure that its activities are coordinated with, and not duplicative of, programs and laboratories of other government agencies.

Directs the President to enter into an agreement with the Institute of Medicine to evaluate the Commission's progress.

Terminates the Commission on June 1, 2020.
Bill 114-S-800 — Health / R&D
Subject: Health

Enhancing the Stature and Visibility of Medical Rehabilitation Research at the NIH Act

(Sec. 2) This bill amends the Public Health Service Act to revise requirements for medical rehabilitation research.

The purpose of the National Center for Medical Rehabilitation Research (NCMRR) is revised to include coordination of research and research training.

The NCMRR must develop and periodically update a comprehensive research plan for medical rehabilitation research. Currently, this research plan is developed and updated by the Eunice Kennedy Shriver National Institute of Child Health and Human Development.

Prior to updating the research plan, the NCMRR must report on progress in achieving the goals and objectives described in the plan.

The Medical Rehabilitation Coordinating Committee must periodically host a scientific conference or workshop on medical rehabilitation research.
Bill 114-S-849 — Health / R&D
Subject: Health

Advancing Research for Neurological Diseases Act of 2016

(Sec. 2) This bill amends the Public Health Service Act to authorize the Department of Health and Human Services (HHS) to improve the collection of epidemiological and surveillance data on neurological diseases and conditions. HHS may provide support to public or nonprofit entities for such purpose. Collected data must be made available for biomedical research.
Bill 114-S-1022 — Health / R&D
Subject: Armed forces and national security

Wounded Warrior Research Enhancement Act

This bill directs the Secretary of Defense to award research grants for:

 actions that can be taken to prevent amputation of limbs, the most effective point for orthotic and prosthetic intervention during patient treatment, orthotic interventions that are most effective in treating the physical effects of traumatic brain injury, patients that benefit most from particular orthotic and prosthetic technologies, orthotic and prosthetic services that best facilitate the return to active duty of members of the Armed Forces, and the effect of aging on the use of prosthetics. The Secretary shall award research grants for the improvement of existing, and development of new, materials and technology used in orthotics and prosthetics.
Bill 114-S-1064 — Health / R&D
Subject: Health

Family Asthma Act

Amends the Public Health Service Act to require the Centers for Disease Control and Prevention (CDC) to collaborate with state and local health departments to: (1) conduct activities regarding asthma, including deterring the harmful consequences of uncontrolled asthma, and disseminating health education and information regarding prevention of asthma episodes and strategies for managing asthma; and (2) develop state plans incorporating public health responses to reduce the burden of asthma, particularly regarding disproportionately affected populations.

 Revises and expands requirements for asthma surveillance activities.

 Requires the CDC to coordinate data collection activities to maximize the comparability of results.

Requires the Department of Health and Human Services to submit an assessment of current activities related to asthma prevention, management, and surveillance along with recommendations for the future direction of asthma activities.
Bill 114-S-1698 — Health / R&D
Subject: Social welfare

(This measure has not been amended since it was passed by the Senate on November 30, 2015. The summary of that version is repeated here.)

Treatment of Certain Payments in Eugenics Compensation Act 

(Sec. 2) This bill excludes payments made under a state eugenics compensation program from classification as income or resources for purposes of determining the eligibility of a recipient of such compensation for, or the amount of, any federal public benefit. The bill defines "state eugenics compensation program" as a state program for compensating individuals who were sterilized under the authority of the state.
Bill 114-S-1865 — Health / R&D
Subject: Health

Anna Westin Act of 2015

This bill requires the Office on Women's Health of the Department of Health and Human Services to revise, promote, and make freely available the BodyWise Handbook and BodyWorks obesity prevention program. The handbook must include information about eating disorders relating to males and females.

The Substance Abuse and Mental Health Services Administration must award grants: (1) to integrate training on eating disorders into existing curricula for health, mental health, and public health professionals; and (2) to states, Indian tribes, tribal organizations, and educational institutions for seminars for school personnel on eating disorders and to make resources available to individuals affected by eating disorders.

The National Institute of Mental Health must make public service announcements on eating disorders.

This bill amends the Public Health Service Act, Employee Retirement Income Security Act of 1974 (ERISA), and Internal Revenue Code to prohibit health insurance coverage from permanently excluding a particular condition from mental health or substance use disorder benefits. Mental health and substance use disorder benefits include residential treatment.
Bill 114-S-1903 — Health / R&D
Subject: Health

Reducing Disparities Using Care Models and Education Act of 2015

This bill requires the Department of Health and Human Services (HHS) to contract with the National Academy of Medicine (formerly known as the Institute of Medicine) to study health disparities, existing programs and policies intended to reduce disparities, and priorities for, and expansion of, programs targeting disparities.

HHS must develop guidelines for entities to develop and implement programs to reduce health disparities. HHS must incorporate these guidelines into its activities.

HHS may award grants for programs to reduce health disparities.

The Innovation Center of the Centers for Medicare & Medicaid Services must test a payment and service delivery model that includes incentives for reducing health disparities.
Bill 114-S-2141 — Health / R&D
Subject: Health

Transparent Ratings on Usability and Security to Transform Information Technology Act of 2015 or the TRUST IT Act

This bill amends the Public Health Service Act to define "information blocking" and "interoperability" for health information technology (IT). Information blocking is preventing, discouraging, or interfering with the access, exchange, or use of electronic health information. Interoperability is the ability of health information systems to exchange information and use exchanged information.

The Office of the National Coordinator for Health Information Technology (ONC) may publish information demonstrating how health IT meets the certification criteria of the voluntary health IT certification program. To be certified, health IT must meet security requirements, incorporate user-centered design, and achieve interoperability.

Entities seeking certification of health IT must attest to meeting requirements regarding information blocking, communication between users and a certification body, and interoperability. The ONC must: (1) recognize a council to establish a rating program to evaluate the interoperability, usability, and security of health IT; (2) publish ratings from that program; (3) convene stakeholders to develop reporting criteria for entities offering health IT; and (4) establish a process for certification bodies to collect confidential feedback.

The ONC may fine entities offering certified health IT that is rated less than satisfactory or entities that do not meet reporting requirements.

The ONC may decertify health IT. The ONC must establish a revolving fund to reimburse users of health IT that becomes decertified for the cost of new certified health IT. Such users are exempt for one year from Medicare payment adjustment under the program that incentivizes meaningful use of electronic health records.

The ONC must publish information on individuals' rights under the Health Insurance Portability and Accountability Act (HIPAA).
Bill 114-S-2248 — Health / R&D
Subject: Health

Congenital Heart Futures Reauthorization Act of 2015

This bill amends the Public Health Service Act to require the Centers for Disease Control and Prevention (CDC) to report annually on its research activities, including a study of congenital heart disease, from birth to adulthood, that considers health care utilization, demographic factors, and outcomes. (Congenital heart disease is a condition caused by a heart defect that is present at birth.)

The CDC must implement an awareness, outreach, and education campaign regarding congenital heart disease.

The National Heart, Lung, and Blood Institute must report on its ongoing research efforts regarding congenital heart disease, future plans for such research, and areas of greatest need for such research.
Bill 114-S-2443 — Health / R&D
Subject: Health

Advancing Standards in Regenerative Medicine Act

This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to facilitate the establishment of a public-private Standards Coordinating Body in Regenerative Medicine and Advanced Therapies. The FDA must work with this body to develop standards to support the development and review of regenerative medicine products.
Bill 114-S-2512 — Health / R&D
Subject: Health

(This measure has not been amended since it was reported to the Senate on March 15, 2016. The summary of that version is repeated here.)

Adding Zika Virus to the FDA Priority Review Voucher Program Act

(Sec. 2) This bill amends the Federal Food, Drug, and Cosmetic Act to add Zika virus disease to the list of tropical diseases under the priority review voucher program, which awards a voucher to the sponsor of a new drug or biological product that is approved to prevent or treat a tropical disease. (A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.)

The bill makes a technical correction to the tropical disease list to refer to filovirus disease, a condition caused by the family of viruses that includes the Ebola virus, instead of the family of viruses.
Bill 114-S-2624 — Health / R&D
Subject: Health

National Biomedical Research Act

This bill establishes and makes deposits to the Biomedical Innovation Fund for initiatives at the National Institutes of Health and the Food and Drug Administration for advancing medical innovation, including the Precision Medicine Initiative, the Brain Research through Advancing Innovative Neurotechnologies Initiative, and the Cancer Moonshot Initiative.
Bill 114-S-2678 — Health / R&D
Subject: Health

Safe Treatments and Opportunities to Prevent Pain Act or the STOP Pain Act

This bill authorizes the National Institutes of Health (NIH) to intensify and coordinate NIH research into the understanding of pain, therapies for chronic pain, and alternatives to opioids (drugs with effects similar to opium) for pain treatments.

The prioritization and direction of federally funded pain research must consider recommendations made by the Interagency Pain Research Coordinating Committee.
Bill 114-S-2713 — Health / R&D
Subject: Health

Advancing Precision Medicine Act of 2016

(Sec. 2) This bill encourages the Department of Health and Human Services (HHS) to carry out a Precision Medicine Initiative to address disease prevention, diagnosis, and treatment. The initiative may include collection of health information from a diverse cohort of individuals. HHS may carry out specified activities relating to the initiative, including coordinating with the Department of Energy to address supercomputing needs.

In implementing the initiative, HHS must: (1) collaborate with the National Institutes of Health (NIH), the Food and Drug Administration, and the Office of the National Coordinator for Health Information Technology; (2) implement secure data sharing; and (3) ensure inclusion of a broad range of participants, considering factors that contribute to health disparities.

(Sec. 3) This bill amends the Public Health Service Act to revise provisions regarding disclosure by researchers of the identifiable, sensitive information of research subjects. HHS must prohibit researchers from disclosing such information from federally funded research to persons not connected to the research. Researchers may apply to have other research covered by this prohibition.

Disclosures of such information are permitted if required by law, necessary for the medical treatment of the research subject, made with the consent of the subject, or made for the purposes of other research that is in compliance with regulations regarding protection of subjects.

(Sec. 4) HHS may exempt identifiable information collected for biomedical research from disclosure under the Freedom of Information Act.

(Sec. 5) The NIH may require recipients of grants or cooperative agreements to share scientific data.

(Sec. 6) The NIH may approve requests by national research institutes to fund high-impact, cutting-edge research through transactions other than contracts, grants, or cooperative agreements. National research institutes must conduct and support high-risk, high-reward research.
Bill 114-S-2742 — Health / R&D
Subject: Health

Promoting Biomedical Research and Public Health for Patients Act

(Sec. 2) This bill amends the Public Health Service Act to revise reporting requirements for the National Institutes of Health (NIH) and certain national research institutes.

(Sec. 3) The Department of Health and Human Services (HHS) must revise policies related to the disclosure of financial conflicts of interest to reduce the administrative burden on researchers while maintaining the integrity and credibility of research findings.

The NIH must reduce administrative burdens related to monitoring subrecipients of grants.

HHS must revise expenditure reporting policies to avoid duplication and minimize burden for recipients of NIH funding.

The NIH, in collaboration with the Department of Agriculture and the Food and Drug Administration (FDA), must revise policies regarding laboratory animals to reduce administrative burdens while maintaining the integrity and credibility of research findings and protection of research animals.

HHS must clarify the applicability of regulations regarding documentation of personnel expenses by grant recipients.

The Office of Management and Budget must establish the Research Policy Board to make recommendations to minimize the administrative burden of federal research policies while maintaining responsible oversight. The board is terminated at the end of FY2020.

(Sec. 4) Contractors making substances and living organisms available for research on behalf of HHS may collect payments on behalf of HHS for incurred costs.

(Sec. 6) HHS must revise the Vaccine Injury Table to include information on vaccines recommended by the Centers for Disease Control and Prevention for pregnant women. A mother and child are individually considered for compensation for a vaccine injury from a vaccine administered during pregnancy.

(Sec. 7) HHS must report on ways to promote innovation in the development of vaccines.

(Sec. 8) The bill revises provisions regarding the clinical trial registry data bank to permit earlier publication of certain data and to categorize clinical trials for combination products.

(Sec. 9) The NIH and the FDA must report on information in the clinical trial registry data bank, activities undertaken to encourage compliance with data bank requirements, and actions to enforce compliance.

(Sec. 10) The Director of NIH is given the authority to appoint the directors of the national research institutes. The term of office of these directors is set to five years, with no limit on the number of reappointments.

(Sec. 11) The National Center for Advancing Translational Sciences may support additional phases of clinical trials.
Bill 114-S-2941 — Health / R&D
Subject: Health

Women and Lung Cancer Research and Preventive Services Act of 2016

This bill requires the Department of Health and Human Services to conduct an interagency study regarding research on lung cancer in women, access to lung cancer preventive services, and public awareness and education campaigns on lung cancer.

The study must include a comprehensive report on research and knowledge gaps related to lung cancer in women in the federal government and recommendations for: (1) a research program that would encourage innovative approaches to eliminate knowledge gaps, (2) the development of a national lung cancer screening strategy with sufficient resources to expand access to screening, and (3) the development of a national public education and awareness campaign on lung cancer in women and the importance of early detection of lung cancer.
Bill 114-S-3115 — Health / R&D
Subject: Health

Pediatric Research Improvement Act of 2016

This bill amends the Public Health Service Act to revise the Pediatric Research Initiative to require collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Human Development and require establishment of a National Pediatric Research Network comprised of pediatric research consortia.

The National Institutes of Health must award funding to entities supporting pediatric research consortia. Supported consortia must, upon request, provide assistance to the Centers for Disease Control and Prevention for patient registries and other surveillance systems.
Bill 114-S-3361 — Health / R&D
Subject: Health

Pulmonary Hypertension Research and Diagnosis Act of 2016

This bill amends the Public Health Service Act to require the Department of Health and Human Services (HHS) to establish the Interagency Pulmonary Hypertension Coordinating Committee. The committee must monitor research and annually summarize research and medical advances regarding pulmonary hypertension.

The committee must develop a comprehensive strategic plan to improve health outcomes for individuals with pulmonary hypertension. The plan must include recommendations regarding pulmonary hypertension diagnosis, research, transplantation criteria, public awareness, and health care delivery.

HHS must report on activities related to improving health outcomes for individuals with pulmonary hypertension. The report must include information regarding pulmonary hypertension epidemiology, treatment, support available to individuals, and research.
Bill 114-S-3431 — Health / R&D
Subject: Health

Scleroderma and Fibrosis Research Enhancement Act of 2016

This bill requires the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to establish the National Commission on Scleroderma and Fibrosis Research. (Scleroderma and fibrosis are connective tissue conditions that cause hardening or scarring of skin and organs.)

The commission must develop a long-term, comprehensive plan for scleroderma and fibrosis research. The plan must: (1) prioritize research that has cross-cutting value and requires coordination across NIH, and (2) include specific steps for implementation of the research.

The commission must establish working groups to make research recommendations for the various organs and systems impacted by fibrotic illness.

The commission must be terminated not later than two years after establishment.

The NIAMS must create the Scleroderma and Fibrosis Working Group to oversee and assist with implementation of the long-term plan.
Bill 114-S-3457 — Health / R&D
Subject: Health

Reducing Medicare Costs through Innovation Act

This bill establishes a Medicare commercialization grant program, through which the Centers for Medicare & Medicaid Services (CMS) shall award grants to eligible small businesses for certain activities related to developing novel eligible medical products and receiving Food and Drug Administration (FDA) approval for such products. CMS shall solicit grant applications annually, with a focus on the diseases or conditions that are the top ten cost drivers in the Medicare program.

To carry out the grant program, CMS shall use amounts allocated under the Small Business Act for the Small Business Innovation Research and Small Business Technology Transfer programs.

The bill also establishes a pilot program (similar to a pilot program that was previously established in regulation) for parallel review of medical products with the purpose of reducing, with respect to certain medical products developed by Medicare commercialization grant recipients, the timeline for FDA approval and Medicare national coverage determinations.

A Medicare commercialization grant applicant may choose to apply for FDA approval of novel medical products either through a traditional process or through the pilot program.